Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd. (TASE:BOLT), has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug. Obecure is focused on development of Histalean® (high dose betahistine) as adjunctive to antipsychotic drug therapy for improved treatment of schizophrenia, bipolar disorder and major depression…

Read more: 
Obecure Is Granted Methods And Composition Patents Covering Adjunctive Use Of Betahistine To Mitigate Weight Gain Associated With Olanzapine

You may also like:

• PositiveID Corporation Successfully Completes Phase I Development Of Its Rapid Virus Detection System
• PositiveID Corporation Successfully Completes Phase I Development Of Its Rapid Virus Detection System
• The Cost Of Delay: State Dental Policies Fail One In Five Children
• Avoiding The Aisles At The Grocery Store Can Help Keep Off Unwanted Pounds
• Repligen Announces FDA And EMA Approval Of Re-analysis Of Images From Phase 3 Trial Of RG1068 For Pancreatic Imaging
• Volcano Introduces VIBE™ RX The World’s Only Vascular Imaging Balloon Catheter
• American Heart Association Rapid Access Journal Report: Blood Clot-related Strokes Decrease Among Whites, But Not Blacks, In Long-term Study
• Repligen Files Investigational New Drug Application With FDA For First Drug Targeting The Core Genetic Defect Of Friedreich’s Ataxia
• BioVex Initiates Phase 1 Clinical Trial With Its Genital Herpes Vaccine, ImmunoVEXHSV2
• Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival In Patients With Metastatic Castrate-Resistant Prostate Cancer